Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Assets: 2018-2025

Historic Assets for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Sep 2025 value amounting to $282.3 million.

  • Arcturus Therapeutics Holdings' Assets fell 23.83% to $282.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $282.3 million, marking a year-over-year decrease of 23.83%. This contributed to the annual value of $344.1 million for FY2024, which is 19.87% down from last year.
  • According to the latest figures from Q3 2025, Arcturus Therapeutics Holdings' Assets is $282.3 million, which was down 8.71% from $309.3 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Assets registered a high of $481.5 million during Q1 2021, and its lowest value of $282.3 million during Q3 2025.
  • In the last 3 years, Arcturus Therapeutics Holdings' Assets had a median value of $388.6 million in 2024 and averaged $384.9 million.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Assets surged by 567.74% in 2021, and later plummeted by 32.43% in 2022.
  • Arcturus Therapeutics Holdings' Assets (Quarterly) stood at $392.8 million in 2021, then grew by 14.66% to $450.4 million in 2022, then declined by 4.66% to $429.4 million in 2023, then dropped by 19.87% to $344.1 million in 2024, then fell by 23.83% to $282.3 million in 2025.
  • Its Assets was $282.3 million in Q3 2025, compared to $309.3 million in Q2 2025 and $331.8 million in Q1 2025.